June 2026 brought a steady mix of clinical guidance and regulatory updates that offer practical opportunities to refine your medical weight loss practice. Between the ACP’s new prescribing hierarchy, the rollout of the Medicare GLP-1 Bridge, and the evolving pipeline of multi-agonists, this month’s developments provide a useful framework to streamline patient access and anchor your clinical discussions in the latest evidence.
In this GLP-1 round up:
The American College of Physicians (ACP) issued a living clinical guideline conditionally recommending semaglutide and tirzepatide as first-line pharmacologic options for eligible nonpregnant adults with overweight or obesity. According to the Annals of Internal Medicine, this recommendation applies when used alongside lifestyle modifications and explicitly asks clinicians to weigh benefits, harms, cost, access, contraindications, and patient preferences.
IAPAM Perspective: This guideline helps providers move beyond “one-size-fits-all” prescribing. It provides a defensible, evidence-based framework for shared decision-making, allowing physicians to structure their consultations around specific patient goals and access realities.
Late-stage trial data released in June underscores the escalating potency of the incretin pipeline. At the ADA conference, TRIUMPH-1 data covered by MedPage Today showed that the investigational triple-agonist retatrutide achieved up to 28.3% mean weight loss at 80 weeks in adults with obesity. Similarly, the SYNCHRONIZE-1 trial published in the New England Journal of Medicine demonstrated that the dual-agonist survodutide achieved up to 13.0% weight loss at 76 weeks.
IAPAM Perspective: This is another vote for the eventual arrival of bariatric-level weight loss via pharmacotherapy. Practices must begin preparing their monitoring protocols now. Managing patients through 20% to 30% weight loss requires intensive nutritional oversight and muscle-preservation strategies that go far beyond standard prescription management.
On June 15, the FDA updated its safety communication regarding unapproved GLP-1 products. The FDA safety statement reported 990 adverse events linked to compounded semaglutide and over 730 for compounded tirzepatide, while explicitly warning that investigational drugs like retatrutide cannot be legally compounded. Concurrently, a NEJM Journal Watch summary highlighted a rare but elevated rate of suspected drug-induced acute pancreatitis among GLP-1 users compared to those on sulfonylureas.
IAPAM Perspective: As adverse event reports rise, physician-led care and rigorous, documented sourcing are critical. Practices must audit their compounding pharmacy partners to ensure strict compliance and actively monitor patients for severe gastrointestinal symptoms, rather than relying on direct-to-consumer app tracking.
The American Gastroenterological Association (AGA ) updated its POWER framework for obesity management. As reported by Medscape Medical News, the new guidance promotes a stepped, personalized approach that integrates lifestyle care, GLP-1 medications, endoscopic therapies, and bariatric surgery.
IAPAM Perspective: Medical weight loss practices should view this not as competition, but as an opportunity. By positioning your clinic as the “hub” for multidisciplinary care, you can build strong referral networks with gastroenterologists and bariatric surgeons for patients who require escalating interventions or combination therapies.
The Medicare GLP-1 Bridge program officially launches on July 1, 2026. According to the Medicare beneficiary fact sheet, eligible Medicare Part D enrollees will have access to specified GLP-1 products for obesity at a capped out-of-pocket cost of approximately $50 per month through the end of 2027.
IAPAM Perspective: This is a practical call-to-action for your front-office staff. Practices should immediately begin verifying Part D eligibility, formulation coverage, and prior authorization requirements for their Medicare patients to ensure a smooth transition when the program goes live.
What is the new ACP guideline for obesity medications? The American College of Physicians (ACP) issued a living guideline conditionally recommending semaglutide and tirzepatide as first-line pharmacologic options for eligible nonpregnant adults, when used in combination with lifestyle modifications.
Are retatrutide and survodutide available for prescription? No. Both retatrutide and survodutide are investigational drugs currently in phase 3 clinical trials and are not yet approved by the FDA for the treatment of obesity.
What is the FDA’s current stance on compounded GLP-1s? The FDA has issued safety warnings regarding unapproved and compounded GLP-1 products due to dosing errors and adverse events. The agency explicitly states that investigational drugs like retatrutide cannot be legally compounded.
When does the Medicare GLP-1 Bridge program start? The Medicare GLP-1 Bridge program officially launches on July 1, 2026, offering eligible Medicare Part D beneficiaries access to specified GLP-1 products for obesity at a capped cost of approximately $50 per month.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss.
Sources
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.